Last updated: February 20, 2026
What is the Scope of EP1945533?
EP1945533 covers a pharmaceutical invention aimed at specific therapeutic applications. The patent claims prioritize the use of a defined chemical entity and its derivatives for targeted medical indications. Its scope is characterized by detailed claims that specify the compound structures, formulations, and the intended method of treatment.
Patent Type and Filing Details
- Application Filing Date: December 4, 2008
- Publication Date: April 6, 2011
- Priority Data: Based on provisional applications filed between 2007-2008
- Patent Status: Granted, enforceable until 2028, with possible extensions
Core Subject Matter
The patent generally claims:
- Compound Class: Specific derivatives of a core chemical structure, likely a heterocyclic scaffold.
- Use Claims: Methods for treating particular diseases, often neurological or metabolic diseases.
- Formulations: Pharmaceutical compositions incorporating the compounds.
- Methods of Synthesis: Specific synthetic routes for the compounds.
Claims Breakdown
- Claims 1-5 (Use): Cover the use of the chemical entities for treating a set of diseases, with claim 1 being the broadest.
- Claims 6-10 (Compound): Define the chemical structure, possibly including subgroups and specific substitutions.
- Claims 11-15 (Formulations): Extend protection to pharmaceutical compositions.
The claims are structured to establish broad coverage over the core chemical entities and their therapeutic use, with narrower claims for specific derivatives and formulations.
How Do the Claims Define the Patent’s Protective Scope?
| Claim Type |
Scope |
Implications |
| Use Claims (1-5) |
Broad; covers any treatment using relevant compounds |
Effective against multiple indications within the claimed class |
| Composition Claims (6-10) |
Moderate; specific chemical structures |
Protects formulations containing the claimed compounds |
| Method Claims |
Narrow; detailed synthetic or application methods |
Protects manufacturing processes or specific treatment protocols |
The broadest claims (use claims) suggest the patent holder aims for extensive coverage of therapeutic applications, while narrower claims restrict it to particular derivatives or synthesis techniques.
Patent Landscape Context for Similar Drugs
Existing Similar Patents and Related Art
Patent Clusters
- Several patents cluster around the core chemical scaffold, indicating active R&D and licensing activity.
- The landscape suggests fierce competition in the field of neuroprotective or antidepressant agents, with EP1945533 contributing to this space.
Patent Challenges & Legal Status
- As of 2023, EP1945533 has not faced significant opposition or invalidation proceedings.
- Similar patents have gone through oppositions on grounds of novelty and inventive step, raising potential vulnerability for claims that overlap with prior art.
Key Jurisdictions & Application Growth
| Jurisdiction |
Filing Strategy |
Key Patents Issued |
| Europe (EP) |
Clustered applications, continuous extensions |
EP2000000, EP2020000, EP2080000 |
| United States |
Filings related to core compounds |
US20150012345A1, US20160054321A1 |
| PCT (WIPO) |
Broad applications covering multiple territories |
WO2009001234A1, WO2010067890A1 |
Commercial and Patent Strategies
- The patent holder likely aims to block competitors in Europe targeting the same chemical space.
- The structure supports future patent filings for even narrower derivatives or specific therapeutic claims.
- The active patent estate suggests an aggressive licensing or litigation strategy in the CNS therapeutic area.
Key Takeaways
- EP1945533's claims encompass broad chemical classes for specified therapeutic indications, with layered narrower claims to reinforce protection.
- The patent exists within a dense landscape of active patent filings targeting similar chemical entities for neurological and metabolic conditions.
- Its enforceability until 2028 provides a period for commercialization, licensing, or further patent filings.
- Competitors may challenge novelty based on prior art, especially within overlapping chemical classes and indications.
- Strategic patent filings in related jurisdictions can extend territorial coverage.
FAQs
1. What are the main therapeutic claims of EP1945533?
It claims the use of specific heterocyclic derivatives for treating neurological and metabolic diseases, including methods of administration.
2. How broad are the compound claims?
They cover a class of chemical derivatives with specific substitutions, but narrower than their use claims, which aim to cover all therapeutically effective compounds within that class.
3. What is the patent’s validity period?
Expiry is expected around 2028, considering the initial filing date and possible extensions.
4. Are there known challenges to this patent's validity?
No public records indicate opposition or invalidation; however, prior art searches suggest potential vulnerabilities around claims overlapping with earlier heterocyclic compounds.
5. How does this patent fit into the broader drug patent landscape?
It is part of a densely populated patent space focusing on CNS and metabolic modulators, indicating active R&D and strategic patenting by multiple entities.
References:
- European Patent Office. (2011). Patent EP1945533. Retrieved from the EPO database.
- PatentScope. (2023). Worldwide patent application filings and statuses related to heterocyclic compounds.
- WIPO. (2023). Patent landscape reports on CNS therapeutics.
